Compare GKOS & NVTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GKOS | NVTS |
|---|---|---|
| Founded | 1998 | 2014 |
| Country | United States | United States |
| Employees | N/A | 190 |
| Industry | Medical/Dental Instruments | Semiconductors |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 5.7B |
| IPO Year | 2015 | 2020 |
| Metric | GKOS | NVTS |
|---|---|---|
| Price | $122.45 | $29.06 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 12 | 5 |
| Target Price | ★ $126.92 | $6.68 |
| AVG Volume (30 Days) | 779.2K | ★ 32.4M |
| Earning Date | 04-29-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $507,442,000.00 | $45,916,000.00 |
| Revenue This Year | $23.32 | N/A |
| Revenue Next Year | $27.43 | $71.28 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 32.33 | N/A |
| 52 Week Low | $73.16 | $4.54 |
| 52 Week High | $148.11 | $25.20 |
| Indicator | GKOS | NVTS |
|---|---|---|
| Relative Strength Index (RSI) | 40.86 | 72.42 |
| Support Level | $79.59 | $7.35 |
| Resistance Level | $123.09 | N/A |
| Average True Range (ATR) | 6.56 | 2.95 |
| MACD | -1.43 | 0.58 |
| Stochastic Oscillator | 5.60 | 97.53 |
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
Navitas Semiconductor Corp develops ultra-efficient gallium nitride (GaN) semiconductors that are revolutionizing power electronics. GaN power ICs integrate GaN power with drive, control, and protection to enable fast charging, high power density, and energy savings for mobile, consumer, enterprise, eMobility, and new energy markets. The company operates as one reportable segment, the design, development, manufacture, and marketing of integrated circuits and related components. Geographically, the company operates in Hong Kong, China, Europe, the United States, Rest of Asia, and Others. The majority of revenue is generated from Hong Kong.